**Stephen Aradi, MD**

12901 Bruce B Downs Blvd, MDC 55, Tampa FL, 33612

[saradi@usf.edu](mailto:saradi@usf.edu); 813-396-9740

**Current Position: Assistant Professor, Neurology**

**University of South Florida Morsani College of Medicine**

**Education**

**8/2011-4/2015 MD**

University of South Florida Morsani College of Medicine

Tampa, Florida

**8/2007-5/2011 BS – Microbiology**

University of South Florida

Tampa, Florida

**Postgraduate Training**

**7/2019-6/2020 Fellowship, Movement Disorders**

USF Health Morsani College of Medicine, Department of Neurology

Tampa, FL

**7/2016-6/2019 Residency, Neurology**

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

**6/2015-6/2016 Internship, Internal Medicine**

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

**Certification**

**2019-present American Board of Psychiatry and Neurology**

**Licensure**

**2019**-**present** **Florida Medical Doctor License**

**Clinical Trial Participation**

**2022-present Site Principal Investigator; “Development of the Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™)”; Huntington Study Group**

**2022-present Sub-investigator, “A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease”; NCT05358821; Sage therapeutics**

**2022-present Sub-investigator, “A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)”; NCT05107128; Sage Therapeutics**

**2022-present Site Principal Investigatory, “A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)”; NCT05111249; Novartis Pharmaceuticals**

**2022-present Site Principal Investigator, “HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States”; NCT03628235; CHDI Foundation, Inc.**

**2022-present Site Principal Investigator, “Web-based Automated Imaging Differentiation of Parkinsonism (AIDP)”; University of Florida**

**2021-present Site Principal Investigator, “PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD”; NCTNCT04556656; Prilenia**

**2020-present Sub-Investigator, “A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)”; NCT04201093; Cerevel Therapeutics, LLC**

**2019-present Sub-investigator,** **“A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease”; NCT03761849; Hoffmann-La Roche**

**2019-present Sub-investigator, “An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies:; NCT03842969; Hoffmann-La Roche**

**2019-2021 Sub-investigator, “Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status (APPRISE)”; NCT03741920; Global Kinetics Corporation**

**Publications**

McLean L, **Aradi S**, Waknin R, Rea B, Camacho MA. HIV-associated dementia presenting predominantly with clinical motor deficits: A case report. Radiol Case Rep. 2022 Jun 18;17(9):3005-3008. doi: 10.1016/j.radcr.2022.05.076. PMID: 35755114; PMCID: PMC9217990.

Scheid BH, **Aradi S**, Pierson RM, Baldassano S, Tivon I, Litt B, Gonzalez-Alegre P. Predicting Severity of Huntington's Disease With Wearable Sensors. Front Digit Health. 2022 Apr 4;4:874208. doi: 10.3389/fdgth.2022.874208. PMID: 35445206; PMCID: PMC9013843.

Jenner P, Mori A, **Aradi SD**, Hauser RA. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Rev Neurother. 2021. doi:10.1080/14737175.2021.1880896

LeWitt PA, **Aradi SD**, Hauser RA, Rascol O. The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S54-S63. doi: 10.1016/j.parkreldis.2020.10.027. Epub 2020 Dec 19. PMID: 33349581.

**Aradi SD**, Hauser RA. Medical Management and Prevention of Motor Complications in Parkinson's Disease. *Neurotherapeutics*. 2020;10.1007/s13311-020-00889-4. doi:10.1007/s13311-020-00889-4

**Aradi S**, Kaiser E, Cucchiara B. Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report. *J Stroke Cerebrovasc Dis*. 2019;28(10):104286. doi:10.1016/j.jstrokecerebrovasdis.2019.07.002

Rosenberg J, **Aradi S**, Pruitt A. Clinical Reasoning: A man with rapidly ascending paralysis. *Neurology*. 2017;89(4):e25-e31. doi:10.1212/WNL.0000000000004156

**Aradi, S**. Pharmacologic pupil: the “blown pupil” of a healthy patient. Neurology E-Pearl, <https://www.aan.com/trainees/e-pearl-of-the-week/june-5-2017>

**Book Chapters**

**Aradi S**, Cucchiara BL. Chapter 24: Dysarthria. In: Cucchiara BL, Price RS, editors. Decision-Making in Adult Neurology. St. Louis: Elsevier; 2021. p. 48-49.

**Educational Activities**

**Aradi, S.** Movement Disorders: Overview. 2 hour lecture given to USF Physician Assistant Program. 10/13/2022.

**Aradi, S.** .Movement Disorders Video Cases. 1 hour interactive conference for USF Neurology residents. 5/26/2022.

**Aradi, S**. Movement Disorders. 1 hour lecture given to 3rd year Neurology Clerkship. 8/5/2022.

**Aradi, S.** Movement Disorders. 1 hour lecture given to 3rd year Neurology Clerkship. 10/15/2021.

**Aradi, S.** Movement Disorders: Overview. 2 hour lecture given to USF Physician Assistant Program. 10/14/2021.

**Aradi, S.** Movement Disorders: Phenomenology and Cases. 2 hour lecture given to USF Neurology residents. 3/11/2021.

**Aradi, S.** Movement Disorders: Overview. 2 hour lecture given to USF Physician Assistant program. 10/7/2020.

**Aradi, S.** Cranial nerves and localization. 2020. 2 hour lecture given to Department of Neurology physician assistants.

**Aradi S.** Movement Disorders: Overview. 1 hour lecture given to 3rd year Neurology Clerkship. 11/1/2019.

**Aradi S,** Siegler J. [**#127 Huntington’s Disease part 2: Current and emerging therapeutics**](https://brainwavesaudio.libsyn.com/127-hd-part-2-current-and-emerging-therapeutics)**.** Podcast episode, Brainwaves: A Neurology Podcast. December 20, 2018.

**National Committee Memberships and Service**

Huntington Study Group: Member, Executive Membership Committee

Huntington Study Group: 2022 Scientific Session Planning Committee

Huntington Study Group: Member, Digital Measures Working Group,

Huntington Study Group: Credentialed Investigator

**Presentations**

**S. Aradi.** Huntington Disease – Updates. USF Neurology Grand Rounds. 3/18/2022. Tampa, FL.

**S. Aradi**, R. Pierson, B. Scheid, S. Baldassano, B. Litt, P. Gonzalez-Alegre. Automatic classification of abnormal movement in Huntington’s disease using wearable sensors and machine learning [abstract]. *Mov Disord.* 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/automatic-classification-of-abnormal-movement-in-huntingtons-disease-using-wearable-sensors-and-machine-learning/. Guided video presentation at the MDS 2020 Virtual Congress.

**Stephen Aradi, MD,** Brian Litt, MD, Pedro Gonzalez-Alegre, MD/PhD. Use of Wearable Sensors in Huntington’s disease. Penn Neurology Grand Rounds. 2019, May 25. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

**Aradi, S.** Sava, V; Sanchez-Ramos, J. Development of Mn-containing chitosan nanoparticles for delivery of RNA interference to the brain. Oral presentation at the 3rd Annual Scholarly Concentrations Program Student Symposium. 2012 October 19. University of South Florida. Tampa, Florida.

**Aradi, S**; Sava, V; Sanchez-Ramos, J. Development of Manganese-containing Chitosan Nanoparticles for Intranasal Delivery of RNA Interference to the Brain. Poster presented at the 11th annual AMA Research Symposium. 2013 November 15-17. National Harbor, Maryland. Awarded First Place in Neurobiology/Neuroscience. Poster presented at 23rd Annual USF Health Research Day. 2013 February 22. USF. Tampa, Florida. Awarded Outstanding Second Year MD student poster in Neurology.

**Aradi, S**; Kotick, JD; Shah, ML; Winkler, A; Lozano, AR; Kasimos, K; Scheff, S; Mufson, EJ; Mervis, RF. Alterations in cortical microcircuitry in Alzheimer’s disease and Mild Cognitive Impairment: Changes in dendritic spines in layer II-III pyramids. Poster presented at the 40th Annual meeting of the Society for Neuroscience. 2010 November 13-17. San Diego, California.

**Aradi, S**; Kotick, K, Shah, M; Winkler, A; Long, R; Kasimos, K; Scheff, S; Mufson, E; Mervis, R. Loss of cortical microcircuitry in Alzheimer’s disease and mild cognitive impairment: Different cortical regions show different patterns of dendritic spine loss. Poster presented at the 24th Annual National Conference on Undergraduate Research. 2010 April 15-17. Missoula, Montana.

**Aradi, S**; Long, R; Kotick, J; Winkler, A; Shah, M; Lozano, A; Scheff, S; Mufson, E; Mervis, R. Cortical Circuitry in Mild Cognitive Impairment and Alzheimer’s disease: Changes in Dendritic Spines. Poster presented at the 20th Annual USF Health Research Day. 2010 February 19. Tampa, Florida. Poster Presented at the USF Neuroscience Research Day. 2010 March 5. Tampa, Florida.

**Honors/Awards**

**2019 – Steven L. Galetta Resident Teaching Award, Penn Neurology**

**2015 – Merck Academic Excellence Award**

**2015 – Senior Student Excellence in Neurology Academics and Research Award**

**2015 – Donn L. Smith Charter Class Scholarship, USF Morsani College of Medicine**

**2015 – Outstanding Achievement in Introduction to Clinical Medicine**

**2014 – Elected member of Gold Humanism Honor Society**

**2014 – Elected junior member to Alpha Omega Alpha Honor Medical Society**

**2011 – King O’Neal Scholar, 4.0 undergraduate GPA**